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protein DBackground: Aboriginal children living in remote communities are at high risk of early and persistent oti-
tis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary patho-
gens. Vaccines with potential to prevent early OM have not been evaluated in this population. We
compared immunogenicity (ELISA and opsonophagocytic activity) of a combination of SynflorixTM
(PHiD-CV10, 10 serotypes and protein D of NTHi) and Prevenar13TM (PCV13, 10 serotypes plus 3, 6A,
and 19A), with recommended schedules.
Methods: This open-label superiority trial randomised (1:1:1) Aboriginal infants at 28 to 38 days of age,
to PCV13 (P) at 2–4-6 months (_PPP), PHiD-CV10 (S) at 2–4-6 months (_SSS), or PHiD-CV10 at 1–2–4 plus
PCV13 at 6 months (SSSP). Primary outcomes (blinded) were immunogenicity against PCV13-only ser-
otypes 3, 6A, 19A, and PHiD-CV10-only protein D at 7 months. Secondary outcomes include immuno-
genicity against all serotypes at 2, 4 and 7 months.
Findings: Between 2011 and 2017, 425 infants were allocated to _PPP(143), _SSS(141) or SSSP(141). An
intention to treat approach including all available data was used. The SSSP group had superior immuno-





Amanda Jane Leach, Edward Kim Mulholland, M. Santosham et al. Vaccine: X 7 (2021) 100086against protein D compared to _PPP (GMC ratio 11.9 (95%CI 9.7 to 14.6)). Immune responses to protein D
and 3, 6A, and 19A in SSSP were not significantly lower (i.e. no harm) than either _SSS or _PPP. For ten
common serotypes responses at 2, 4 and 7 months were superior for SSSP (following 1-, 2-, and 4- doses)
than _SSS and _PPP (following 0-, 1-, and 3- doses). At 4 months, _SSS was superior to _PPP.
Reactogenicity and hospitalisations were rare and unrelated to the intervention.
Interpretation: From two months, the 1–2–4–6-month combined schedule (SSSP) was safe and signifi-
cantly more immunogenic than 2–4–6-month schedules. The earlier responses may be beneficial in
high-risk populations.
 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In remote communities of northern Australia, we previously
demonstrated that the onset of otitis media (OM) in Aboriginal
infants was preceded by acquisition of bacterial pathogens that
colonise the nasopharynx (NP) within weeks of birth [1]. Persistent
and ongoing nasopharyngeal acquisition and co-colonisation with
multiple strains of Streptococcus pneumoniae (Spn) and non-
typeable Haemophilus influenzae (NTHi) cause OM, chronic hearing
loss and associated disadvantage throughout critical early learning
years [2–4]. Risk factors include overcrowding, smoke exposure,
limited handwashing with soap, and under-resourced primary
health care services [2,5]. Prevention strategies that address these
risk factors have not been evaluated in high quality studies. Pneu-
mococcal conjugate vaccines (PCVs) prevent OM caused by vaccine
serotypes, and at the time of designing this trial (2009) one PCV
with protein D of NTHi as conjugate (11Pn-PD) also prevented
NTHi-OM and NTHi nasopharyngeal carriage [6,7]. Two PCVs are
licenced in Australia as a 2–4-6 month infant series; 10-valent
pneumococcal Haemophilus influenzae protein D conjugate vaccine
(PHiD-CV10, SynflorixTM, S) and 13-valent PCV (PCV13, Preve-
nar13TM, P). Our hypothesis was that both PCVs could be used to
broaden immune responses to OM pathogens. At commencement
of our trial, there were few data available on safety or efficacy of
neonatal PHiD-CV10 or PCV13 immunisation in high-risk infants.
PCV7 trials had demonstrated no difference in immunogenicity of
newborn versus standard schedules [8,9]. Immunological data
indicated that three doses of PHiD-CV10 provided significantly
higher levels of anti-protein D antibodies than two doses [10],
and an additional study demonstrated that a single dose of
PCV13 at 12 months of age and following a PCV7 infant series
was immunogenic against the 6 additional serotypes [11].
Our overall objective was therefore to evaluate safety and
immunogenicity of a combination PCV schedule of PHiD-CV10 (S)
given at 1–2–4 months plus PCV13 (P) given at 6 months (SSSP)
compared to either vaccine alone when given at 2–4-6 months
(_SSS or _PPP). The aim being to provide early immune responses
against OM pathogens when measured at 2, 4, and 7 months of
age. [12] We also aimed to show that the ratio of vaccine doses
in the combination did not compromise immunogenicity com-
pared to standard schedules. Head-to-head immunogenicity com-
parisons for the ten serotypes common to PHiD-CV10 and PCV13
are reported at 2, 4, and 7 months.2. Methods
2.1. Trial design
The trial protocol has been published, [12] brief methods are
provided below. The PREVIX_COMBO trial is an open-label, alloca-
tion concealed, primary outcome assessor (immunologist) blinded,
randomized controlled trial with three parallel groups (1:1:1). The2
PREVIX_COMBO trial was approved by the relevant Human
Research Ethics Committees.2.2. Setting and participants
The trial took place in five remote Aboriginal communities in
the Northern Territory and Western Australia. [12] Inclusion crite-
ria: Aboriginal or Torres Strait Islander male and female infants liv-
ing in a participating remote community, 28 to 38 days of age,
eligible for National Immunisation Program routine vaccines.
Exclusion criteria: Gestational age < 32 weeks. Not the eldest of
multiple births. Research nurses were notified of all pregnancies
and obtained written informed consent or assent from parents at
infant age 28 to 38 days of age.2.3. Interventions
SynflorixTM (GSK, Rixensart, Belgium) is a 10-valent PCV in
which 1 mg of polysaccharide for each of serotypes 1, 5, 6B, 7F,
9 V, 14, and 23F, and 3 mg of serotype 4 polysaccharide are conju-
gated to protein D of Haemophilus influenzae; 3 mg serotype 18C
polysaccharide is conjugated to 8 mg tetanus toxoid, and 3 mg of
serotype 19F polysaccharide is conjugated to 5 mg diphtheria tox-
oid. Prevenar/Prevnar 13TM (Pfizer, New York, NY) is a 13-valent
PCV in which each dose contains 2 mg of polysaccharide for 12 ser-
otypes and 4 mg of polysaccharide for serotype 6B, each conjugated
to cross-reacting material CRM197 of diphtheria. See Table 1 for
schedule of procedures.
Nomenclature used in this manuscript are: italics P and S indi-
cate vaccine (Prevenar13TM or SynflorixTM) received at the time
point of interest, and to indicate the comparison of interest. Vac-
cine schedules studied were _PPP, _SSS, and SSSP at 1,2,4,6 months.2.4. Relevant concomitant care
Throughout this study, the Australian Indigenous infant vacci-
nation schedule was EngerixBTM at birth, RotarixR at 2–4 months,
InfanrixR Hexa, and (for non-study participants) Prevenar13 at 2–
4-6 months. Study staff provided treatment or referral for all con-
comitant conditions according to local guidelines.2.5. Immunogenicity outcomes
Serotype-specific IgG concentration was measured using a
modified 3rd generation ELISA based on WHO recommendations
against 13 PCV serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A,
19F, and 23F) and 11 non-PCV polysaccharide vaccine (PPV) sero-
types (2, 8, 9 N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F). Protein
D of H. influenzae (provided by GSK) IgG was measured and
expressed in ELISA units, EL.U/mL. Multiplex opsonophagocytosis
activity (MOPA) was measured for all PCV serotypes, expressed
as a geometric mean titre (GMT). [13]
Table 1
Schedule of enrolment, interventions, and assessments.
Study period
allocation post allocation
Study visit number 1 1 2 3 4 5
Age (months) 1 1 2 4 6 7
Eligibility screen x
Informed consent signed x
Randomisation x
Interventions – Pneumococcal conjugate vaccines
Prevenar13 (_PPP) _ P P P
Synflorix (_SSS) _ S S S
COMBO (SSSP) S S S P
RotarixR x x
InfanrixR Hexa x x x
Outcome assessments
Risk factor data and interviews
Fixed e.g. sex, birthweight, gestational age, maternal education x
Not fixed e.g. household occupancy, smoke exposure, breastfeeding x x
Blood draw (heel, finger prick, or venepuncture) x* x* x
Ear assessment
Tympanometry x x x x x
Video otoscopy x x x
Nasopharyngeal swab x§ x x x x
General health (skin, chest, nose, temp, weight, length) and medical record review x x x x x
* blood draw occurs at either 2 months or 4 months of age (decided by a random process). § NP swab collection at one month of age commenced late 2014 (NT) or 2015
(WA). S is PHiD-CV10 (SynflorixTM). P is PCV13 (Prevenar13TM)
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425 participants were expected to provide 339 evaluable
infants and 270 sera at 7 months [12]. This was estimated to pro-
vide 99% power to detect at least a 30% (absolute) difference in the
proportion of infants with immunogenicity above threshold
against 3, 6A, or 19A, and 90% power to detect at least a 21% differ-
ence in protein D responses [12]. All available outcome data were
used (Fig. 1).2.7. Randomisation and blinding
Eligible infants were randomly allocated (1:1:1) by the study
nurses who called the NHMRC CTC randomisation service, to
_PPP, _SSS, or SSSP. Stratification was by community [12]. The
immunologist was blinded to the intervention allocation [12].
Research nurses were trained in giving vaccines, paediatric blood
collection, and in standardised ear and general health checks. See
Table 1 for schedule of procedures.2.8. Statistical methods
Vaccine group comparisons of IgG (lg/mL) were tested with the
Mann-Whitney U test, and Fisher’s exact test for the proportion of
infants above threshold IgG; 95% confidence intervals (95%CI) were
calculated. IgG concentrations below threshold for detection were
given the lowest detectable value multiplied by 05. All tests were
2-sided and a P value < 005 was considered statistically signifi-
cant. All data were analysed using Stata/IC 15.1 [14].2.9. Data safety monitoring
The study was overseen by an independent Data Safety and
Monitoring Board (iDSMB). Adverse events (reactogenicity at
intensity level 3) were solicited on days 0 to 3 following vaccina-
tion, including pain, fever, irritability, drowsiness, loss of appetite.
Level 3 intensity generally prevents normal activity. All admissions
to hospital were reported as serious adverse events [12].3
2.10. Role of funding source
The funders had no role in design, collection, analysis, interpre-
tation of data, writing the report or decision to submit for publica-
tion. As corresponding author, AJL had full access to all the data in
the study and had final responsibility for the decision to submit for
publication. AJL was not paid by any agency to write this article.3. Results
3.1. Participant flow, recruitment and baseline data
Five communities[12] commenced between September 2011
and August 2014. Randomisations completed on 21st September
2017. Of 1018 pregnancy notifications, 593 were excluded, 425
infants were randomised to _PPP (143), _SSS (141) or SSSP
(141). 213 and 212 infants were randomly allocated to a blood
draw at 2 or 4 months, respectively. 396 (93%) infants were ran-
domised within 28 to 38 days of age. Overall, infant birth charac-
teristics were similar between groups (Table 2). At 7 months,
there were 403 (95%) sera of adequate volume for testing serotypes
3, 6A, and 19A, and 393 (92%) for protein D (Fig. 1 and Table 3).
Exclusion of protocol deviations or violations made no difference
to our findings.3.2. Immunogenicity outcomes
Co-primary outcomes: Serotypes 3, 6A, 19A, and protein D: supe-
riority of SSSP at 7 months
Broadened immunogenicity of the combination schedule at
7 months of age was confirmed. The SSSP group had significantly
higher protein D IgG than _PPP (GMC ratio ~ 12, 57% difference
in proportion of infants with IgG  100 EL.U/mL, Table 3) and sig-
nificantly higher serotype 3, 6A, and 19A immunogenicity than
_SSS (GMC ratios ~ 3 to ~ 8, 18% to 61% difference in
proportions  035 lg/ml) (Table 3, Figs. 2 and 3). Opsonophago-
cytic activity (OPA) GMT ratios support our primary hypothesis
of superior immunogenicity against serotypes 3, 6A, and 19A in
1018 Assessed for eligibility 593 Excluded
326 Ineligible
112 Stillbirth/miscarriage/unknown
         8 Birth pending
145 Refused or no contact 
        2 Withdrawn
425 Randomised at 1 month of age
213 randomised for blood draw at 2 months
212 randomised for blood draw at 4 months 
141 allocated to Synflorix 141 allocated to combination143 allocated to Prevenar13
143 allocated for blood draw at 7 months
6 withdrawn /1 inadequate sample
136 included in ITT analysis
      1 out of window period
        0 violation
135 included in ATP analysis
71 allocated for blood draw at 4 months
3 withdrawn / 0 inadequate sample
69 included in ITT analysis
      2 out of window period
       0 violation
67 included in ATP analysis
67 allocated for blood draw at 4 months
5 withdrawn / 2 inadequate sample
60 included in ITT analysis
9 out of window
0 violation
51 included in ATP analysis
72 allocated for blood draw at 2 months
3 withdrawn /0 inadequate sample*
69 included in ITT analysis
     0 out of window
     0 violation
69 included in ATP analysis
74 allocated for blood draw at 2 months
2 withdrawn /1 inadequate sample
71 included in ITT analysis
     3 out of window 
       1 violation
67 included in ATP analysis
67 allocated for blood draw at 2 months
1 withdrawn /1 inadequate sample
65 included in ITT analysis
     5 out of window
       0 violation
60 included in ATP analysis
74 allocated for blood draw at 4 months
5 withdrawn /1 inadequate sample
69 included in ITT analysis
        9 out of window period
        0 violation
60 included in ATP analysis
141 allocated for blood draw at 7 months
4 withdrawn /1 inadequate sample
136 included in ITT analysis
14 out of window period
      0 violation
122 included in ATP analysis
141 allocated for blood draw at 7 months
9 withdrawn /1 inadequate sample
131 included in ITT analysis
12 out of window period
     2 = violation
117 included in ATP analysis
Fig. 1. Trial profile. * This Figure shows number of sera with adequate volumes for testing serotypes 3, 6A, and 19A. See Tables for numbers of sera with adequate volumes for
Protein D, ten additional serotypes, and OPA.
Table 2
Baseline Characteristics.
Characteristics Prevenar13 (_PPP) Synflorix (_SSS) Combo (SSSP)
N = 143 N = 141 N = 141
Sex /gender Male 77/143 (54%) 69/141 (49%) 70/141 (50%)
Female 66/143 (46%) 72/141 (51%) 71/141 (50%)
Gestational age at birth (Weeks) Mean (SD) 384 (142) 384 (140) 381 (162)
Birth weight (kg) Mean (SD) 315 (047) 319 (049) 307 (053)
Weight at randomisation (kg) Mean (SD) 426 (054) 424 (061) 404 (068)
Age at randomisation (days) Mean (SD) 331 (333) 325 (377) 325 (394)
Community 1 Wurrumiyanga 29/143 (20%) 32/141 (23%) 30/141 (21%)
2 Wadeye 53/143 (37%) 50/141 (36%) 50/141 (36%)
3 Kununurra 26/143 (18%) 25/141 (18%) 27/141 (19%)
4 Alice Springs 7/143 (5%) 6/141 (4%) 6/141 (4%)
5 Maningrida 28/143 (20%) 28/141 (20%) 28/141 (20%)
Have any of your other children had runny ears? Yes 19/98 (19%) 22/97 (23%) 19/93 (20%)
How many children under 5 will live with you and baby? Median (Q1-Q3) 200 (100-200) 200 (100-250) 200 (100-200)
Are you breast feeding only? Yes 98/117 (84%) 98/115 (85%) 93/114 (82%)
Are you breastfeeding? Yes 120/124 (97%) 117/124 (94%) 116/121 (96%)
Are you bottle feeding only? Yes 4/123 (3%) 6/120 (5%) 4/119 (3%)
Are you bottle feeding? Yes 24/122 (20%) 26/125 (21%) 25/119 (21%)
Did you smoke when you were pregnant? Yes 58/119 (49%) 60/124 (48%) 61/120 (51%)
Does anyone smoke at your house? Yes 27/124 (22%) 31/125 (25%) 22/121 (18%)
Do you cook with or sit near a wood fire? Yes 23/123 (19%) 22/125 (18%) 28/121 (23%)
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Fig. 4).
Secondary outcomes: Serotypes 3, 6A, 19A, and protein D: no
immune compromise of SSSP at 7 months
We found no overall immune compromise of the single dose P
in SSSP versus 3-dose _PPP at 7 months of age, since at least 87%
infants had IgG above threshold against serotypes 3, 6A, and 19A
following a single dose of PCV13 in SSSP. GMCs in the SSSP group
were significantly higher (GMC ratio 148) than _PPP against sero-
type 3 and significantly lower against serotypes 6A and 19A (GMC4
ratios 049 and 076) (Table 3, Figs. 2 and 3). In support of our sec-
ondary hypothesis regarding no immunological ‘harm’ of the SSSP
schedule compared to _PPP, all serotype 3, 6A, and 19A GMTs
were  8 (GMTs 49, 279, and 226, respectively). Higher GMTs in
the SSSP group against serotypes 3 and 19A (GMT ratios 1.35 and
1.05) did not reach statistical significance, whereas serotype 6A
GMT was significantly lower (GMT ratio 0.37) (Table 6 and Fig. 4).
We found no protein D immune compromise in the early 1–2–
4-month SSSP schedule compared to the 2–4-6 month _SSS sched-
ule (GMC ratio 093) (Table 3).
Table 3
Vaccine group comparisons of serotype-specific GMCs (mg/mL) (Ratio, 95%CI, p value) and proportion of infants with IgG  035 mg/mL or  10 mg/mL (Difference, 95%CI, p value)
against serotypes 3, 6A, 19A, 10 common serotypes, and  100 EU/mL against protein D, at 7 months.
7 months _PPP _SSS SSSP SSSP vs _PPP SSSP vs _SSS _PPP vs _SSS
GMC GMC GMC Ratio 95%CI p Ratio 95%CI p Ratio 95%CI p
n 136 131 136
3 148 026 219 148 (123, 178) <0001 827 (669, 1021) <0001 560 (455, 690) <0001
6A 525 042 259 049 (035, 069) <0001 614 (444, 849) <0001 1247 (976, 1594) <0001
19A 347 097 263 076 (058, 099) 0045 273 (205, 363) <0001 359 (278, 465) <0001
n 132 129 132
Protein D 88 1121 1047 1192 (972, 1461) <0001 093 (074, 118) 073 008 (006, 010) <0001
n 117 115 120
1 3.96 2.18 5.32 1.34 (1.05, 1.71) 0.015 2.44 (1.93, 3.08) <0.001 1.81 (1.47, 2.24) <0.001
4 4.27 3.35 3.88 0.91 (0.72, 1.15) 0.15 1.16 (0.94, 1.43) 0.49 1.27 (1.02, 1.59) 0.017
5 2.66 1.07 2.74 1.03 (0.83, 1.28) 0.88 2.57 (2.09, 3.15) <0.001 2.49 (2.01, 3.08) <0.001
6B 2.80 2.44 15.05 5.38 (3.82, 7.57) <0.001 6.17 (4.70, 8.12) <0.001 1.15 (0.84, 1.57) 0.21
7F 4.02 2.33 3.95 0.98 (0.79, 1.22) 0.48 1.69 (1.37, 2.09) <0.001 1.72 (1.41, 2.10) <0.001
9 V 3.12 2.01 4.69 1.50 (1.21, 1.87) <0.001 2.33 (1.89, 2.88) <0.001 1.55 (1.26, 1.92) <0.001
14 8.55 6.23 8.13 0.95 (0.70, 1.29) 0.62 1.30 (0.98, 1.74) 0.035 1.37 (1.02, 1.84) 0.0064
18C 2.92 3.14 2.92 1.00 (0.76, 1.31) 0.98 0.93 (0.71, 1.22) 0.74 0.93 (0.72, 1.20) 0.88
19F 4.77 5.79 12.95 2.72 (2.03, 3.64) <0.001 2.24 (1.62, 3.09) <0.001 0.82 (0.62, 1.09) 0.032
23F 3.21 1.89 7.63 2.38 (1.76, 3.21) <0.001 4.04 (3.11, 5.26) <0.001 1.70 (1.28, 2.26) <0.001
% 0.35 % 0.35 % 0.35 Diff 95%CI p Diff 95%CI p Diff 95%CI p
n 136 131 136
3 96 37 99 3 (-1, 7) 028 61 (53, 70) <0001 58 (49, 67) <0001
6A 98 54 87 11 (-17, 5) <0001 32 (22, 43) <0001 44 (35, 52) <0001
19A 100 78 96 4 (-8, 1) 003 18 (10, 26) <0001 22 (15, 29) <0001
% 100 % 100 % 100
n 132 129 132
Protein D 41 99 98 57 (48, 66) <0001 1 (-4, 1) 062 58 (-67, 50) <0001
% 0.35 % 0.35 % 0.35
n 117 115 120
1 99 100 99 0 (-2, 2) 1.0 1 (-2, 1) 1.0 1 (-3, 1) 1.0
4 97 100 100 3 (0, 5) 0.12 0 (0, 0) 3 (-5, 0) 0.25
5 97 92 99 2 (-2, 5) 0.37 7 (2, 12) 0.0089 5 (0, 11) 0.082
6B 89 97 99 10 (4, 16) <0.001 2 (-2, 5) 0.36 9 (-15, 2) 0.017
7F 100 100 99 1 (-2, 1) 1.0 1 (-2, 1) 1.0 0 (0, 0)
9 V 98 97 100 2 (-1, 4) 0.24 3 (0, 6) 0.12 1 (-3, 5) 0.68
14 99 98 99 0 (-2, 2) 1.0 1 (-2, 4) 0.62 1 (-2, 4) 0.62
18C 97 97 97 0 (-5, 5) 1.0 1 (-5, 4) 1.0 1 (-5, 4) 1.0
19F 99 97 98 1 (-4, 2) 1.0 1 (-3, 5) 0.68 2 (-2, 5) 0.37
23F 96 95 99 3 (-1, 7) 0.12 4 (0, 9) 0.061 1 (-5, 6) 0.77
%>1.0 %>1.0 %>1.0
n 136 131 136
3 71 5 83 13 (3, 22) 0021 79 (71, 86) <0001 66 (58, 74) <0001
6A 93 18 69 24 (–33, 16) <0001 51 (41, 62) <0001 76 (68, 84) <0001
19A 88 47 79 9 (-18, 0) 0074 32 (21, 43) <0001 41 (31, 51) <0001
n 117 115 120
1 95 83 95 0 (-5, 6) 1.0 12 (4, 19) 0.0053 11 (4, 19) 0.0057
4 96 94 94 2 (-7, 4) 0.77 0 (-6, 6) 1.0 2 (-4, 8) 0.57
5 86 54 90 4 (-5, 12) 0.43 36 (26, 47) <0.001 32 (21, 43) <0.001
6B 78 84 98 20 (12, 28) <0.001 13 (6, 20) <0.001 7 (-17, 3) 0.24
7F 94 86 95 1 (-5, 7) 0.78 9 (1, 16) 0.024 8 (0, 16) 0.05
9 V 92 86 98 5 (0, 11) 0.081 11 (4, 18) 0.0014 6 (-2, 14) 0.14
14 93 95 94 1 (-5, 7) 0.80 1 (-6, 5) 1.0 2 (-8, 4) 0.78
18C 84 90 83 0 (-10, 9) 1.0 6 (-15, 2) 0.19 6 (-15, 3) 0.25
19F 94 91 98 3 (-2, 9) 0.21 6 (0, 12) 0.047 3 (-4, 9) 0.46
23F 79 78 98 20 (12, 27) <0.001 20 (12, 28) <0.001 0 (-10, 11) 1.0
P = PCV13 or Prevenar13; S = PHiD-CV10 or Synflorix. Italic P or S represents doses received at each age. GMC, geometric mean concentration. 95%CI, 95% confidence interval.
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responses to accelerated SSSP schedule
At 4 months of age post 2-month dose in the _PPP group
immunogenicity was superior to post 1–2 month doses in the SSSP
group against serotype 3 (GMC ratio 0.35), but not against sero-
types 6A or 19A (GMC ratios 1.15 and 1.17, respectively) (Table 4,
Figs. 2 and 3). Responses to protein D in the SSSP group were sig-
nificantly higher than _PPP (GMC ratio 20) and _SSS (GMC ratio
8). Protein D immunogenicity was similar following either two or
three doses (Tables 3 and 4).
At 2 months of age there were no group differences in serotype
3, 6A, or 19A immunogenicity (Table 5, Figs. 2 and 3). Responses to5
protein D following one-month dose in the SSSP group were signif-
icantly higher than the non-vaccinated groups (GMC ratio ~ 3, ~40%
difference in the proportion of infants with GMCs  100 EL.U/mL)
(Table 5). Protein D immunogenicity was similar following first
dose given at either one month or two months of age (Tables 4
and 5).
Secondary outcomes: Serotypes 3, 6A, 19A, and protein D: Head-
to-head comparisons
At 4 months, following first dose in the standard 2–4-6 sched-
ules, protein D immunogenicity was significantly lower (GMC ratio
04) in the _PPP group (Table 4). Responses to serotypes 3, 6A, and
19A were all low (GMCs 022 to 042 mg/mL). Surprisingly, the _PPP
Fig. 2. Vaccine group comparisons of IgG GMCs, mg/mL (95%CI) against serotypes 3, 6A, 19A, and ten common serotypes at 2, 4, and 7 months of age. P = PCV13 or Prevenar13;
S = PHiD-CV10 or Synflorix. GMC geometric mean concentration. 95%CI, 95% confidence interval. Seroprotection threshold of 035 mg/mL and putative threshold of 10 mg/mL
for pneumococcal serotypes, are indicated by red dashed lines. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
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(~35% increase in proportion of infants with IgG  035 mg/mL), but
not 6A or 19A (Table 4, Figs. 2 and 3).
At 7 months of age, the _PPP protein D immunogenicity was sig-
nificantly lower (GMC ratio 008) than _SSS (Table 3) and immuno-
genicity against serotypes 3, 6A, and 19A was significantly higher
(GMC ratios 36 to 125 and GMT ratios ~ 6 to 163) (Tables 3 and
6, Figs. 2 to 4).
Secondary outcomes: Ten common serotypes at 7 months of age:
4-dose versus 3-dose schedules at 7 months
Compared to the 3-dose _PPP group, the 4-dose SSSP GMCs were
significantly higher against five common serotypes 1, 6B, 9 V, 19F,
and 23F (ratios 134 to 538). The proportion of infants with
IgG  035 mg/mL was significantly higher against serotype 6B
(89% versus 99%). The proportion of infants with IgG  10 mg/mL
was significantly higher against serotypes 6B and 23F (Differences
20% for each) (Table 3, Figs. 2 and 3).6
Compared to the 3-dose _SSS group, the 4-dose SSSP GMCs
were significantly higher against eight common serotypes (ratios
130 to 617), other than serotypes 4 and 18C. The proportion of
infants with IgG  035 mg/mL was significantly higher against
serotypes 6B (Difference 10%) and 5 (Difference 7%), and at the
higher threshold (IgG  10 mg/mL), against seven serotypes (Dif-
ferences 6% to 36%), other than serotypes 4, 14 and 18C (Table 3,
Figs. 2 and 3).
OPA GMTs in all groups were  8 against all ten common sero-
types. OPA confirms significantly higher GMTs of the 4-dose SSSP
schedule against most serotypes (other than 4, 14 and 18C), and
particularly against serotypes 1, 5, 6B, and 19F compared to _PPP
(GMT ratios ~ 23 to 42), and also against 7F, 9V, and 23F when
compared to _SSS (GMT ratios 29 to 105). The proportion of
infants with GMT  8 was significantly higher against serotype
6B (Difference 10% compared to _PPP), 1, and 23F (Differences
19% and 15% compared to _SSS) (Table 6, Fig. 4).
Fig. 3. Vaccine group comparisons of the proportion of infants (%, 95%CI) with IgG  035 mg/mL against serotypes 3, 6A, and 19A, and ten common serotypes, at 2, 4, and
7 months of age. P = PCV13 or Prevenar13; S = PHiD-CV10 or Synflorix. GMC geometric mean concentration. 95%CI, 95% confidence interval.
Amanda Jane Leach, Edward Kim Mulholland, M. Santosham et al. Vaccine: X 7 (2021) 100086Secondary outcomes: Ten common serotypes at 7 months of age:
head to head 3-dose comparisons of _PPP and _SSS
The _PPP group GMCs were significantly higher against sero-
types 1, 4, 5, 7F, 9 V, 14, and 23F (ratios 127 to 249) and signifi-
cantly lower only against serotype 19F (ratio 082). Compared to
_SSS, the _PPP proportion of infants with IgG  035 mg/mL was sig-
nificantly lower against serotype 6B (97% versus 89%, respectively).
At the higher threshold _PPP was significantly lower against sero-
types 1 (95% and 83%, respectively) and 5 (86% and 54%, respec-
tively) (Table 3, Figs. 2 and 3).
The _PPP group GMTs were significantly higher against sero-
types 4, 6B, 7F and 23F (GMT ratios 1.25 to 67), although there
were no significant differences in the proportion of infants with
GMT  8. Low OPA titres against serotype 1 in both _PPP and _SSS7
(GMTs 206 and 13, and proportions with GMT  8 of 64% and
61%, respectively) may be clinically relevant (Table 6, Fig. 4).
Secondary outcomes: Ten common serotypes at 4 months of age:
early responses to accelerated SSSP schedule
At 4 months, all ten common vaccine type GMCs (082 to
400 mg/mL) in the 2-dose SSSP group were significantly higher
than both the single-dose _PPP (ratios 23 to 104) and _SSS (ratios
207 to 51) groups (Table 4 and Fig. 2).
Similarly, the proportions of infants with IgG  035 mg/mL in
the 2-dose SSSP group were between 71% and 97% against the
ten common serotypes, which were significantly higher than 1-
dose _PPP (Differences 20% to 69%) other than against serotype
19F (which was not significantly lower). Proportions were also
Fig. 4. Vaccine group comparisons of OPA GMTs (95%CI) against serotypes 3, 6A, and 19A, and ten common serotypes, at 7 months of age. P = PCV13 or Prevenar13; S = PHiD-
CV10 or Synflorix. OPA opsonophagocytic activity. GMT geometric mean titre. 95%CI, 95% confidence interval. Seroprotection threshold GMT of 8 indicated by red dashed
lines. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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(Differences 14% to 44%) other than serotypes 1, 4 and 14. The 2-
dose SSSP group had significantly higher proportions of infants
with IgG  10 mg/mL against all common serotypes compared to
1-dose _PPP (Differences 39% to 74%) and 1-dose _SSS (Differences
24% to 51%) (Table 4, Fig. 3).
Secondary outcomes: Ten common serotypes at 4 months of age –
head to head 1-dose comparisons
Head-to-head comparisons of immunogenicity against the ten
common serotypes following a single dose at 2 months showed
superiority of _SSS. The _PPP group had lower GMCs (ratios 026
to 059) against nine serotypes. The proportion of infants with
IgG above  035 mg/mL was significantly higher in the _SSS group
(Differences 13% to 48%) against serotypes 1, 4, 5, 6B, 7F, and 9 V.
Serotype 19F was significantly higher in the _PPP group (Difference
22%). The _SSS group also had significantly higher proportions of
infants with IgG  10 mg/mL (Differences 10% to 36%) against ser-
otypes 1, 4, 7F, 9 V, 14, and 23F (Table 4, Figs. 2 and 3).
Secondary outcomes: Ten common serotypes at 2 months of age –
early responses to accelerated SSSP schedule.
At 2 months, non-vaccinated infant GMCs were < 035 mg/mL
against serotypes 1, 4, 5, 6B, 7F, 9 V, 18C, and 23F. Less than ~ 40%
infants had GMCs  035 mg/mL, and ~ 10% had GMCs  10 mg/mL
against these serotypes (Table 5, Figs. 2 and 3).
At 2 months the SSSP group GMCs were higher than the non-
vaccinated _PPP and _SSS groups against all vaccine serotypes
other than 6B and 23F for which non-significant increases were
detected. GMCs differences were highest against serotypes 1, 4
and 7F (GMC ratios 11, 8, 7). The proportion of infants with
IgG  035 mg/mL was between ~ 20% (serotype 14) and 81% (ser-
otype 1) higher in the SSSP group. At the higher threshold differ-
ences were 20% to 50% higher (Table 5, Fig. 3).
PPV-Non-PCV serotypes8
For PPV-non-PCV serotypes, GMCs were generally  035 mg/mL
at each timepoint, other than against 9N and 15B, in all vaccine
groups. At 7 months of age, the 4-dose SSSP group serotype 9N
GMC was significantly higher than either _PPP or _SSS (GMC ratios
1.5 and 2.3, respectively) and the proportions of infants with 9N
GMCs above either threshold were also significantly higher (Differ-
ences 7% to 27%). There were also some significant vaccine group
differences for serotypes 2, 8, 11A, and 33F (data not shown).
Safety
Adverse events were rare. There were two reports of fever, one
post dose 2 (386C) and one post dose 3 (385C) in the SSSP
group. There were no unsolicited adverse events (day 0 to next
dose).
There were 72 serious adverse events (hospital admissions) and
one death. There were 23, 21, and 29 SAEs in the _PPP, _SSS, and
SSSP groups, respectively. Sixty-two SAEs were unrelated (21, 18,
23, respectively), nine were unlikely to be related including the
one death, and two were possibly related. The most common
causes of hospitalisation in respective groups were, bronchiolitis
(n = 14, 7, 12), other respiratory (n = 3, 3, 3), skin infections
(n = 1, 4, 3), and gastroenteritis (n = 4, 1, 2).4. Discussion
Studies in small populations living in remote areas with high
disease burden are difficult to conduct. To our knowledge this is
the first RCT to report immunogenicity of a PCV schedule that
includes a combination of PCV formulations within the first
6 months of life. The study clearly demonstrates the safety and
immunogenicity of the 1–2-4–6-month combination of PHiD-
CV10 and PCV13 as a SSSP primary course schedule. We also
demonstrate absence of potential deleterious effects due to other
Table 4
Vaccine group comparisons of serotype-specific GMCs (mg/mL) (Ratio, 95%CI, p value) and proportion of infants with IgG  035 mg/mL or  10 mg/mL (Difference, 95%CI, p value)
against serotypes 3, 6A, 19A, 10 common serotypes, and  100 EU/mL against protein D, at 4 months.
4 months _PPP _SSS SSSP SSSP vs _PPP SSSP vs _SSS _PPP vs _SSS
GMC GMC GMC Ratio 95%CI p Ratio 95%CI p Ratio 95%CI p
n 69 60 69
3 031 008 011 035 (026, 048) <0001 136 (101, 184) 002 385 (274, 542) <0001
6A 022 018 026 115 (086, 154) 046 143 (107, 190) 0025 124 (095, 161) 016
19A 042 034 049 117 (089, 154) 059 143 (106, 193) 0055 122 (092, 162) 015
n 66 54 63
Protein D 61 150 1231 2012 (1421, 2848) <0001 821 (582, 1158) <0001 041 (028, 059) <0001
n 65 59 66
1 0.49 1.21 2.05 4.16 (2.90, 5.97) <0.001 1.70 (1.22, 2.36) 0.0036 0.41 (0.28, 0.60) <0.001
4 0.35 1.13 3.03 8.54 (5.82, 12.54) <0.001 2.67 (1.85, 3.86) <0.001 0.31 (0.21, 0.48) <0.001
5 0.31 0.74 1.54 5.04 (3.73, 6.80) <0.001 2.07 (1.58, 2.71) <0.001 0.41 (0.30, 0.56) <0.001
6B 0.16 0.20 0.86 5.30 (3.68, 7.63) <0.001 4.22 (2.84, 6.27) <0.001 0.80 (0.58, 1.09) 0.25
7F 0.45 0.90 2.21 4.87 (3.52, 6.73) <0.001 2.46 (1.82, 3.32) <0.001 0.50 (0.35, 0.72) <0.001
9 V 0.17 0.64 1.72 10.40 (7.38, 14.67) <0.001 2.68 (1.87, 3.85) <0.001 0.26 (0.18, 0.37) <0.001
14 0.69 1.34 4.00 5.84 (3.90, 8.74) <0.001 2.99 (1.98, 4.51) <0.001 0.51 (0.36, 0.74) <0.001
18C 0.20 0.34 1.74 8.61 (5.60, 13.26) <0.001 5.10 (3.27, 7.96) <0.001 0.59 (0.38, 0.91) 0.017
19F 0.77 0.68 1.78 2.31 (1.63, 3.27) <0.001 2.62 (1.71, 4.01) <0.001 1.13 (0.80, 1.61) 0.22
23F 0.15 0.27 0.82 5.32 (3.80, 7.45) <0.001 3.05 (2.08, 4.47) <0.001 0.57 (0.41, 0.79) 0.0025
% 0.35 % 0.35 % 0.35 Diff 95%CI p Diff 95%CI p Diff 95%CI p
n 69 60 69
3 41 3 6 35 (-48, –22) <0001 2 (-5, 10) 068 37 (25, 50) <0001
6A 26 18 23 3 (-17, 11) 084 5 (-9, 19) 052 8 (-7, 22) 040
19A 61 50 58 3 (-19, 13) 086 8 (-9, 25) 038 11 (-6, 28) 029
% 100 % 100 % 100
n 66 54 63
Protein D 27 67 98 71 (60, 82) <0001 32 (19, 45) <0001 39 (-56, –23) <0001
% 0.35 % 0.35 % 0.35
n 65 59 66
1 54 88 97 43 (30, 56) <0.001 9 (0, 18) 0.083 34 (-49, 20) <0.001
4 43 88 97 54 (41, 67) <0.001 9 (0, 18) 0.083 45 (-60, 30) <0.001
5 38 83 97 59 (46, 71) <0.001 14 (3, 24) 0.013 45 (-60, 29) <0.001
6B 14 27 71 57 (44, 71) <0.001 44 (28, 60) <0.001 13 (-27, 1) 0.076
7F 55 83 97 42 (29, 54) <0.001 14 (3, 24) 0.013 28 (-43, 12) 0.001
9 V 23 71 92 69 (57, 81) <0.001 21 (8, 34) 0.0022 48 (-64, –33) <0.001
14 77 92 97 20 (9, 31) <0.001 5 (-3, 14) 0.25 15 (-27, 2) 0.03
18C 29 46 82 53 (38, 67) <0.001 36 (20, 52) <0.001 17 (–33, 0) 0.065
19F 88 66 91 3 (-7, 14) 0.58 25 (11, 39) <0.001 22 (7, 36) 0.0051
23F 17 32 76 59 (45, 73) <0.001 44 (28, 59) <0.001 15 (-30, 0) 0.059
% 1.0 % 1.0 % 1.0
n 69 60 69
3 13 2 3 10 (-19, 1) 0055 1 (-4, 6) 10 11 (3, 20) 002
6A 7 0 6 1 (-10, 7) 10 6 (0, 11) 012 7 (1, 13) 0061
19A 13 12 20 7 (-5, 20) 036 9 (-4, 21) 023 1 (-10, 13) 10
n 65 59 66
1 28 56 80 53 (38, 67) <0.001 24 (8, 40) 0.0039 28 (-45, 12) 0.0019
4 18 54 91 72 (61, 84) <0.001 37 (22, 51) <0.001 36 (-52, 20) <0.001
5 14 24 74 60 (47, 74) <0.001 51 (35, 66) <0.001 10 (-24, 4) 0.17
6B 3 7 47 44 (31, 57) <0.001 40 (27, 54) <0.001 4 (-11, 4) 0.42
7F 23 44 85 62 (48, 75) <0.001 41 (25, 56) <0.001 21 (-37, 5) 0.021
9 V 2 36 76 74 (63, 85) <0.001 40 (24, 56) <0.001 34 (-47, 21) <0.001
14 34 59 88 54 (40, 68) <0.001 29 (14, 43) <0.001 25 (-42, 8) 0.0066
18C 8 19 68 60 (48, 73) <0.001 50 (35, 65) <0.001 11 (–23, 1) 0.11
19F 34 27 73 39 (23, 55) <0.001 46 (30, 61) <0.001 7 (-9, 23) 0.44
23F 0 10 52 52 (39, 64) <0.001 41 (27, 56) <0.001 10 (-18, 2) 0.01
P = PCV13 or Prevenar13; S = PHiD-CV10 or Synflorix. Italic P or S represents doses received at each age. GMC, geometric mean concentration. 95%CI, 95% confidence interval.
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schedules.
Key findings of our study are that at 7 months of age following a
single dose of PCV13 in the SSSP group, immunogenicity against
serotypes 3, 6A, and 19A was not significantly lower than the 3-
dose _PPP, other than some measures of the 6A response. The
opsonophagocytic activity supports these findings. We also found
that the 4-dose schedule provided significantly higher immuno-
genicity including OPA against most common serotypes (1, 5, 6B,
7F 9 V, 19F, and 23F) compared to 3-dose schedules, particularly
compared to _SSS. Additional key findings include the substantial
response to the first dose of PHiD-CV10 given at one month of
age, and superiority of the 2-month first dose of PHiD-CV10 over9
PCV13 against eight of ten common serotypes. The poor response
to the 2-month dose of PCV13 against all 13 serotypes is a new
finding that also warrants further investigation. Key findings in
relation to protein D were that the first dose of PHiD-CV10 at
one-month was immunogenic, and by 4 months of age, following
two doses, levels were as high as those achieved following three
doses. If immunogenicity also correlates with early impacts on
NP carriage and otitis media (which we will report in separate pub-
lications), an early 2-dose PHiD-CV10 schedule, followed by a sin-
gle dose of PCV13 should be evaluated for use in high-risk
populations.
To our knowledge this is the first report indicating the potential
for mixed vaccine primary course schedules to have benefits
Table 5
Vaccine group comparisons of serotype-specific GMCs (mg/mL) (Ratio, 95%CI, p value) and proportion of infants with IgG  035 mg/mL or  10 mg/mL (Difference, 95%CI, p value)
against serotypes 3, 6A, 19A, 10 common serotypes, and  100 EU/mL against protein D, at 2 months.
2 months _PPP _SSS SSSP SSSP vs _PPP SSSP vs _SSS _PPP vs _SSS
GMC GMC GMC Ratio 95%CI p Ratio 95%CI p Ratio 95%CI p
n 69 71 65
3 007 007 007 099 (074, 132) 095 093 (072, 120) 079 094 (071, 126) 078
6A 031 032 030 098 (072, 135) 091 095 (071, 126) 087 096 (072, 129) 099
19A 070 059 049 070 (047, 104) 0075 083 (058, 118) 022 118 (082, 169) 051
n 69 60 60
Protein D 45 42 133 295 (199, 437) <0001 320 (225, 456) <0001 108 (074, 160) 076
n 69 72 68
1 0.17 0.17 1.90 11.37 (8.09, 15.99) <0.001 11.07 (8.00, 15.32) <0.001 0.97 (0.74, 1.28) 0.89
4 0.11 0.11 0.88 7.89 (5.10, 12.21) <0.001 8.37 (5.54, 12.63) <0.001 1.06 (0.76, 1.49) 0.49
5 0.24 0.22 1.12 4.72 (3.37, 6.61) <0.001 5.12 (3.82, 6.87) <0.001 1.09 (0.78, 1.51) 0.54
6B 0.30 0.27 0.32 1.07 (0.69, 1.65) 0.59 1.17 (0.80, 1.70) 0.44 1.10 (0.75, 1.60) 0.94
7F 0.22 0.22 1.56 6.99 (4.79, 10.18) <0.001 7.18 (5.01, 10.29) <0.001 1.03 (0.72, 1.46) 0.44
9 V 0.17 0.18 0.77 4.57 (3.13, 6.67) <0.001 4.35 (3.08, 6.14) <0.001 0.95 (0.68, 1.34) 0.93
14 0.94 1.19 1.79 1.91 (1.26, 2.89) 0.0042 1.50 (0.96, 2.34) 0.078 0.79 (0.49, 1.25) 0.39
18C 0.19 0.19 0.49 2.60 (1.77, 3.84) <0.001 2.66 (1.79, 3.93) <0.001 1.02 (0.69, 1.50) 0.89
19F 0.63 0.60 0.85 1.34 (0.93, 1.94) 0.13 1.41 (1.00, 1.99) 0.066 1.05 (0.78, 1.42) 0.66
23F 0.22 0.19 0.29 1.36 (0.94, 1.96) 0.13 1.50 (1.07, 2.12) 0.022 1.11 (0.77, 1.59) 0.51
% 0.35 % 0.35 % 0.35 Diff 95%CI p Diff 95%CI p Diff 95%CI p
n 69 71 65
3 3 1 3 0 (-6, 6) 10 2 (-3, 7) 061 1 (-3, 6) 062
6A 45 39 38 6 (–23, 10) 049 1 (-17, 15) 10 5 (-11, 22) 061
19A 74 72 63 11 (-26, 5) 020 9 (-24, 7) 036 2 (-13, 17) 085
% 100 % 100 % 100
n 69 60 60
Protein D 22 15 58 37 (21, 52) <0001 43 (28, 59) <0001 7 (-7, 20) 037
% 0.35 % 0.35 % 0.35
n 69 72 68
1 13 18 94 81 (71, 91) <0.001 76 (66, 87) <0.001 5 (-17, 7) 0.49
4 9 11 75 66 (54, 79) <0.001 64 (51, 76) <0.001 2 (-12, 7) 0.78
5 38 28 90 52 (39, 66) <0.001 62 (49, 75) <0.001 10 (-6, 25) 0.28
6B 43 38 43 1 (-17, 16) 1.0 5 (-11, 21) 0.61 6 (-10, 22) 0.50
7F 33 21 85 52 (38, 66) <0.001 64 (52, 77) <0.001 13 (-2, 27) 0.13
9 V 17 19 75 58 (44, 71) <0.001 56 (42, 69) <0.001 2 (-15, 11) 0.83
14 72 75 93 20 (8, 32) 0.0029 18 (6, 29) 0.0058 3 (-17, 12) 0.85
18C 25 26 65 40 (25, 55) <0.001 38 (23, 54) <0.001 2 (-16, 13) 0.85
19F 77 72 74 3 (-18, 11) 0.70 1 (-13, 16) 1.0 5 (-10, 19) 0.57
23F 33 22 34 0 (-15, 16) 1.0 12 (-3, 26) 0.14 11 (-4, 26) 0.19
% 1.0 % 1.0 % 1.0
n 69 71 65
3 0 0 0 0 (0, 0) 0 (0, 0) 0 (0, 0)
6A 7 10 6 1 (-10, 7) 1.0 4 (-13, 5) 0.54 3 (-12, 7) 0.76
19A 30 35 23 7 (–22, 8) 0.44 12 (-27, 3) 0.14 5 (-20, 11) 0.59
n 69 72 68
1 1 3 68 66 (55, 78) <0.001 65 (53, 77) <0.001 1 (-6, 3) 1.0
4 1 1 43 41 (29, 53) <0.001 41 (29, 53) <0.001 0 (-4, 4) 1.0
5 6 4 53 47 (34, 60) <0.001 49 (36, 62) <0.001 2 (-6, 9) 0.71
6B 19 8 16 3 (-15, 10) 0.82 8 (-3, 19) 0.20 11 (-1, 22) 0.086
7F 10 11 68 58 (44, 71) <0.001 57 (43, 70) <0.001 1 (-11, 9) 1.0
9 V 7 6 38 31 (18, 44) <0.001 33 (20, 45) <0.001 2 (-6, 10) 0.74
14 51 56 74 23 (7, 39) 0.0081 18 (2, 34) 0.034 5 (-21, 12) 0.61
18C 6 11 31 25 (13, 37) <0.001 20 (7, 33) 0.0061 5 (-14, 4) 0.37
19F 29 25 43 14 (-2, 30) 0.11 18 (2, 33) 0.032 4 (-11, 19) 0.70
23F 4 8 13 9 (0, 18) 0.077 5 (-5, 15) 0.42 4 (-12, 4) 0.49
P = PCV13 or Prevenar13; S = PHiD-CV10 or Synflorix. Italic P or S represents doses received at each age. GMC, geometric mean concentration. 95%CI, 95% confidence interval.
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research is needed to determine whether the substantial 3, 6A, and
19A immunogenicity following first dose of PCV13 at 6 months in
the SSSP schedule was primed by the preceding PHiD-CV10 doses.
Certainly, the GMCs achieved following first dose of PCV13 in the
_PPP group were very low compared to those after the first dose
of PCV13 in the SSSP group. For a 6A and 19A response it is plausi-
ble that there has been cross-reaction with 6B and 19F in the pre-
ceding PHiD-CV10 doses. However, the lack of 6A and 19A
responses in the _SSS group suggests that cross-reaction was not
involved.
The proportion of infants having above the aggregate correlate
of protection against invasive pneumococcal disease (IPD)10of  035 mg/mL was at least 89% against all common serotypes
and all groups at 7 months of age. Whilst an aggregate correlate
of protection of  035 mg/mL is required to demonstrate protec-
tion from IPD for licensing, serotype-specific correlates vary sub-
stantially. For serotypes 3, 6A, and 19A, correlates estimated
from 706 cases of IPD in the UK and Northern Ireland were 283,
016 and 100 mg/mL, respectively [15]. Our corresponding GMCs
at 7 months were 219, 259, and 263 mg/mL in the SSSP group
and 148, 525, and 347 mg/mL in the _PPP group. Both groups,
and particularly the _PPP group have inadequate serotype 3
responses according to this UK correlate of protection. Our sero-
type 3 OPA GMT was also lower in the _PPP group (GMT 36) com-
pared to SSSP (GMT 49), but this difference did not reach statistical
Table 6
Vaccine group comparisons of serotype-specific OPA GMTs (Ratio, 95%CI, p value) and proportion of infants with IgG above threshold (8) (Difference, 95%CI, p value), against
serotypes 3, 6A, and 19A, and 10 common serotypes at 7 months.
7 mo _PPP _SSS SSSP SSSP vs _PPP SSSP vs _SSS _PPP vs _SSS
n GMT n GMT n GMT Ratio 95%CI p Ratio 95%CI p Ratio 95%CI p
3 47 3638 53 610 65 4905 135 (084, 218) 026 805 (543, 1193) <0001 597 (377, 945) <0001
6A 43 76482 43 469 57 27925 037 (016, 082) 0026 5948 (2676, 13220) <0001 16291 (7910, 33556) <0001
19A 104 21599 98 632 109 22609 105 (063, 175) 032 3580 (2170, 5905) <0001 3420 (2236, 5230) <0001
1 39 20.59 49 13.04 62 60.44 2.94 (1.37, 6.31) 0.0071 4.63 (2.30, 9.32) <0.001 1.58 (0.77, 3.26) 0.21
4 102 363.02 107 259.38 107 366.77 1.01 (0.57, 1.80) 0.87 1.41 (0.81, 2.46) 0.013 1.40 (0.81, 2.42) 0.019
5 106 450.19 108 384.34 108 1013.68 2.25 (1.72, 2.95) <0.001 2.64 (2.08, 3.34) <0.001 1.17 (0.90, 1.53) 0.18
6B 91 611.28 101 488.89 71 2072.72 3.39 (1.98, 5.79) <0.001 4.24 (2.78, 6.48) <0.001 1.25 (0.70, 2.24) 0.027
7F 41 899.69 46 453.20 61 1325.47 1.47 (0.87, 2.50) 0.27 2.92 (1.86, 4.60) <0.001 1.99 (1.10, 3.58) 0.0032
9 V 46 404.30 50 210.24 63 748.53 1.85 (0.91, 3.75) 0.049 3.56 (1.83, 6.91) <0.001 1.92 (0.90, 4.11) 0.031
14 43 621.52 54 465.16 59 510.10 0.82 (0.34, 1.96) 0.21 1.10 (0.50, 2.40) 0.92 1.34 (0.55, 3.25) 0.19
18C 47 411.92 55 388.63 58 413.56 1.00 (0.49, 2.04) 0.70 1.06 (0.54, 2.10) 0.85 1.06 (0.53, 2.12) 0.87
19F 46 177.33 53 220.53 60 738.14 4.16 (2.10, 8.26) <0.001 3.35 (1.55, 7.24) <0.001 0.80 (0.39, 1.68) 0.14
23F 46 436.28 54 65.51 59 684.86 1.57 (0.74, 3.35) 0.3 10.45 (5.21, 20.99) <0.001 6.66 (3.02, 14.68) <0.001
n %>8 n %>8 n %>8 Diff 95%CI p Diff 95%CI p Diff 95%CI p
3 47 83% 53 23% 65 91% 8% (-5, 21) 026 68% (55, 81) <0001 60% (45, 76) <0001
6A 43 95% 43 23% 57 88% 8% (-18, 3) 029 64% (49, 80) <0001 72% (58, 86) <0001
19A 104 94% 98 37% 109 91% 3% (-10, 4) 044 54% (43, 65) <0001 57% (47, 68) <0001
1 39 64 49 61 62 81 17 (-1, 35) 0.10 19 (3, 36) 0.033 3 (-17, 23) 0.83
4 102 91 107 91 107 91 1 (-8, 7) 1.0 0 (-8, 8) 1.0 1 (-7, 8) 1.0
5 106 100 108 100 108 100 0 (0, 0) 0 (0, 0) 0 (0, 0)
6B 91 90 101 96 71 100 10 (4, 16) 0.0051 4 (0, 8) 0.14 6 (-13, 1) 0.15
7F 41 98 46 100 61 100 2 (-2, 7) 0.40 0 (0, 0) 2 (-7, 2) 0.47
9 V 46 93 50 96 63 98 5 (-3, 13) 0.31 2 (-4, 9) 0.58 3 (-11, 6) 0.67
14 43 91 54 91 59 90 1 (-12, 11) 1.0 1 (-12, 10) 1.0 0 (-12, 12) 1.0
18C 47 96 55 96 58 97 1 (-7, 8) 1.0 0 (-7, 7) 1.0 1 (-8, 7) 1.0
19F 46 98 53 89 60 95 3 (-10, 4) 0.63 6 (-4, 16) 0.3 9 (0, 19) 0.12
23F 46 93 54 81 59 97 3 (-5, 12) 0.65 15 (4, 26) 0.013 12 (-1, 25) 0.13
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only the SSSP group could deliver serotype 3 immunogenicity. Both
groups had adequate serotype 19A responses. The serotype 6A
GMC in the SSSP group (259 mg/mL), although significantly lower
than the GMC in the _PPP group (525 mg/mL), is well above the
0.16 mg/mL correlate for protection [15].
Our data clearly demonstrate superior immunogenicity of the
early 1–2-month SSSP schedule. At 2 months, SSSP was superior
to non-vaccinated groups for almost all shared serotypes, and all
GMCs were above UK-proposed serotype-specific correlates, other
than 19F. This response to first dose of PHiD-CV10 at one month of
age is a significant finding for populations at high-risk of early
onset infections. A vaccine response at this age cannot be assumed,
given potential for maternal antibody masking, or failure to
respond. Nasopharyngeal carriage occurs within weeks of life in
this population [1]. Whilst NP carriage has been observed to prime
PCV responses, others have reported that prior carriage compro-
mises immune responses to the colonising serotype [13,16]. The
hierarchy of carriage serotypes in this population prior to com-
mencement of this trial was (descending) 16F, 15A, 23F, 11A,
35B, 19F, and 15B [2]. It is plausible that NP carriage has had a role
in immune responses. The interactions between carriage, immuno-
genicity, and otitis media will be reported in subsequent papers.
As mentioned above, in the head-to-head comparisons of _PPP
and _SSS, we found poor or no responses to first dose of PCV13
given at 2 months of age. The PCV13 responses to the 2-month
dose were below UK serotype-specific correlates of IPD protection
for all nine common serotypes, other than serotypes 14 and 18C.
Interestingly, and consistent with the strong responses to the
one-month dose of PHiD-CV10, the first dose of PHiD-CV10 given
at 2 months was superior to PCV13 for all common serotypes other
than serotype 19F, eight of which were above UK serotype-specific
correlates of protection. This also suggests that our choice to use
PHiD-CV10 for first dose in our early combination schedule was
possibly the right choice, and that subsequent combination trials
could take this into account. We note that serotype 19F is one of11two serotypes in PHiD-CV10 that is not protein D-conjugated
which may in part explain lack of PHiD-CV10 superiority for this
serotype.
tIn the absence of immune correlates of protection against NP
carriage, we have reported the proportion of infants having an
IgG concentration  10 mg/mL. For serotypes 3, 6A, and 19A this
was at least 71% in the _PPP group and at least 69% in the SSSP
group. For the ten common serotypes, at least 78% achieved this
level of immunogenicity in the _PPP and _SSS groups, respectively
(other than against serotype 5 in the _SSS group which was 54%),
and 83% in the SSSP group. Seroincidence has been proposed as a
proxy for NP carriage (i.e. a rise in antibody above that at post vac-
cination being indicative of NP carriage) [17]. We compared the
serotype-specific GMCs (95%CIs) with published correlates for 9
of 10 common serotypes (serotype 1 absent) [17]. Above protective
levels (non-overlapping 95%CIs) were achieved at 7 months in the
SSSP group against serotypes 4, 5, 6B, 7F, 18C and 19F. Point esti-
mate GMCs were above estimated thresholds against serotypes
9V and 23F, but with overlapping 95%CIs. Serotype 14 was lower
but not significantly lower. GMCs above proposed NP carriage cor-
relates were achieved at younger ages in the SSSP group for sero-
types 4 (at 4 months of age) and serotype 5 (at 2 months of age).
Nasopharyngeal carriage data from this trial will help determine
vaccine impact on early acquisition and immune responses.
We also found small but significant protein D responses to the
one-month dose of PHiD-CV10 in our combination SSSP group. Fol-
lowing the second dose at 2 months of age, levels of protein D IgG
were almost 10-fold higher and were similar to levels after three
doses in either the SSSP or _SSS groups at 7 months of age. This sug-
gests that for protein D, a third dose within the primary course
offers no further immune benefit. We also show that the shift from
standard 2–4-6-months to 1–2–4-months did not compromise
protein D responses achieved at 7 months, inter alia demonstrating
the persistence of protein D IgG to 3 months after the third dose of
S in the SSSP group.
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although studies commonly report the proportion of participants
with IgG  100 EU/mL. Evidence of a clinical or microbiological
impact of anti-protein D antibodies on NTHi infection or carriage
is variable [6,7,18]. Our study found levels of protein D antibodies
of around 1200 EU/mL at 7 months of age, similar to levels
reported from other post-primary studies [7,10]. Naturally derived
protein D antibody has been associated with reduced NTHi-AOM
[19]. In our study we detected very small increases in protein D
GMCs in the _PPP group (i.e. naturally derived) at 2, 4, and
7 months. Our systematic review showed no evidence of reduced
NP carriage of NTHi following early primary course doses [20].
Small studies have found protein D vaccine responses to be protec-
tive of respiratory symptoms[21] and to reduced NTHi lower air-
way infection [22]. Our cross-sectional studies during PCV7,
PHID-CV10, and PCV13 eras found a significant reduction in
NTHi-culture-positive middle ear infections in PHiD-CV10-
vaccinees and a small reduction in AOM [23,24]. A consistent trend
in these studies is that there is potentially a compartmental effect
of PHiD-CV10; with reduced NTHi infections and clinical improve-
ments in the ear and lung, not paralleled by reduced NP carriage.
Our data on NP carriage and otitis media from this study will
add further to the slowly emerging evidence on vaccine-induced
NTHi protection.
There are few published trials comparing mixed PHiD-CV10 and
PCV13 primary course schedules or head-to-head trials with which
to compare our findings. Two head-to-head trials have recently
been reported [25,26]. The Papua New Guinean trial [26] compared
PHiD-CV10 with PCV13 given at 1–2-3 months of age; at 4 months,
serotype 3, 6A, 19A as well as 7F, 19F and 23F GMCs were higher in
the PCV13 group. The Vietnamese trial reported immunogenicity
against the ten common serotypes 4 weeks after the 2-dose pri-
mary course of PCV13 versus PHiD-CV10; [25] the 2-dose PCV13
had significantly higher proportion of infants with IgG
concentration  035 mg/mL against serotypes 6B and 23F, and
higher OPA GMTs against serotypes 1, 9 V, and 23F. Neither trial
evaluated mixed schedules nor reported responses after the first
dose. A recent systematic review of the interchangeability of mixed
schedules opined that the limited data available, primarily from
boosting with an alternative vaccine to primary course, were reas-
suring, but gaps in evidence limited application to policy decisions,
particularly for primary course interchangeability [27]. They
included data from one 3-arm RCT (published as conference
abstract in 2017) that compared 2 + 1 SS-S, PP-S and PS-S; the
PS-S arm having mixed vaccines within the infant series (PCV13
at 2 months and PHiD-CV10 at 4 months). Immunogenicity was
measured post-primary only; serotype 6A, 19A, and 3 responses
were lower in the PS-S group compared to PP-S, which is consistent
with our findings of low responses to first PCV13 in infant series.
In 2018 Australia’s national Immunisation Program made the
lowest recommended age for the first dose of PCV13 6 weeks,
but did not require a repeated first dose unless given before 28 days
of age. The results of our study confirm the safety and immuno-
genicity of a first dose of PHiD-CV10 at one month. Although most
Australian children are now recommended to have a 2 + 1 PCV
schedule, for Aboriginal children living in regions with high inci-
dence of pneumococcal disease a 3 + 1 schedule continues to be
recommended. Our data suggest that the persistent problem of
severe early-onset otitis media in these children may benefit from
scheduling the first dose at 4 weeks of age and that clinical
outcomes should be further evaluated. Our data also support
flexibility in timing of first dose and opportunistic vaccine
recommendations.
Importantly we have demonstrated the safety and superior
immunogenicity of combining PCV13 and PHiD-CV10 in a primary
course schedule that commences at one month of age, with no12immunological compromise or safety concerns of the ratio or tim-
ing of vaccine doses (SSSP).Panel 1. Research in context.
Evidence before this study.
In 2009 there was uncertainty regarding the superiority of
pneumococcal conjugate vaccines in preventing otitis media
caused by pneumococcus and non-typeable Haemophilus
influenzae. Whilst there were emerging data on interchange-
ability of PCVs between primary and booster doses, no trial
evaluated safety or immunogenicity of combined PCVs
within the primary course. No data from head-to-head trials
were available to determine which PCV provided superior
immunogenicity during the first months of life. No study
had evaluated safety or immunogenicity of a 4-dose primary
course schedule.
Added value of this study.
This study confirms broader immunogenicity, without
compromise (immunological or adverse events) of the com-
bination 4-dose schedule of PHiD-CV10 at 1–2-4 months plus
PCV13 at 6 months of age. Outcomes at 2, 4, and 7 months of
age are valuable for high-risk populations. For the first time,
we have shown that responses following single dose PCV13
given at 6 months (and following the 1–2-4 PHiD-CV10), are
comparable to the 3-dose PCV13 response. We confirmed
superior immunogenicity of the early one- and two- month
PHiD-CV10 doses in the SSSP group against most common
serotypes at 2 and 4 months, and additional benefit of the
fourth dose against most of the common serotypes, particu-
larly 6B, 19F, and 23F. Head-to-head comparisons revealed
superiority of the 2-month dose in the _SSS over _PPP for
most common serotypes and poor responses to all 13 sero-
types following the 2-month dose of PCV13. The clinical rele-
vance of protein D antibody concentration is poorly
understood, our study indicated that substantial concentra-
tions can be achieved by 4 months of age following the early
1–2 SSSP schedule.
Implications of all the available evidence.
This study provides evidence that PHiD-CV10 can elicit
protective immune responses when given as early as one
month of age. PHiD-CV10 and PCV13 can be combined safely
in a 3:1 primary course ratio to provide broader coverage and
higher antibody levels. We document poor immunogenicity
of first dose PCV13 given at 2 months of age. Further research
is needed to better understand the potential beneficial inter-
actions between these PCVs and how their differences can
be used to tailor schedules to meet the needs of different
populations. Interchangeability of PCVs in the primary course
will simplify vaccine use in countries that already use these
vaccines alternatively for primary and booster doses.5. Contributors
AJL (Principal Investigator, PI) conceived the study, led funding
applications, obtained ethical approvals and other regulatory
approvals, undertook consultations, reporting and has overseen
day-to-day management and implementation of the trial, man-
aged, analysed and interpreted the data, created figures (with MC
and VO) and wrote the manuscript. NWmanaged the trial, staffing,
participant recruitment and retention, specimen collection,
reported to Ethics committees and data safety monitoring board,
managed quality of data and read the final version of the manu-
script. BA assisted participant recruitment and retention, specimen
collection, managed quality of data and read the final version of the
manuscript. JB managed microbiology and serology collections,
database and data quality, and read the final version of the manu-
Amanda Jane Leach, Edward Kim Mulholland, M. Santosham et al. Vaccine: X 7 (2021) 100086script. MC wrote the data analysis plan in the protocol, analysed
data, generated tables and figures and read the final version of
the manuscript. VO analysed data, generated tables and figures
and read the final version of the manuscript. EKM advised on study
design, assisted with funding application, participated in investiga-
tor meetings, advised on risk management and read the final ver-
sion of the manuscript. MS advised on study design, assisted with
funding application, participated in investigator meetings, advised
on risk management and read the final version of the manuscript.
PJT advised on study design, assisted with funding application, par-
ticipated in investigatormeetings, advised on riskmanagement and
read the final version of the manuscript. NJB advised on study
design, assisted with funding application, participated in investiga-
tor meetings and advised on risk management, particularly in rela-
tion to engagement of Aboriginal Medical Services and cultural
matters. PM advised on study design, assistedwith funding applica-
tion, participated in investigator meetings, advised on risk manage-
ment and read the final version of the manuscript. HS-V advised on
study design, assisted with funding application, participated in
investigator meetings, advised on laboratory protocols, particularly
microbiology, and reviewed the final version of the manuscript. SS
advised on study design, assisted with funding application and read
the final version of the manuscript. AB advised on study design,
assisted with funding application, participated in investigator
meetings and advised on laboratory protocols, particularly
immunogenicity. PL advised on laboratory protocols, particularly
immunogenicity, and read the final version of the manuscript. RA
advised on study design, assisted with funding application. JC
advised on study design, assisted with funding application and read
the final version of the manuscript. JM advised on study design,
assisted with funding application and advised with statistical mat-
ters. VK advised on study design, assisted with funding application
and advised on immunisation policy implications. PSM advised on
study design, assisted with funding application, participated in
investigator meetings, advised on risk management and provided
day-to-day supervision of clinical training, and read the final ver-
sion of the manuscript.
Additional investigators: PREVIX staff (current or at least one
year): PREVIX research managers and research nurses: Nicole Wil-
son (Manager), Beth Arrowsmith, Tracy Grierson, Carolyn Gage-
Pearson (admin), Nicole Weinert, Natalie Bert, Zeina Hayes, Mela-
nie Schwarz, Julie Wheeler, Bronwyn Nankervis, Laura Bell, Jessica
Young, Kelly Whykes, Sabine Sprenger, Melisa Downie, Valerie
Coomber, Kate Ranford, Rachel Sharp, Elissa Rowe, Jodie Howes,
Chantelle Dowling, Claire Haynes, Christine Byrne, Niki Emmett,
Sarah Carlisle, Fiona Hildebrand, Kate Dohle, Cathy O’Driscoll.
PREVIX laboratory team: Jemima Beissbarth (Manager), Vanya
Hampton, Nerida Liddle, ChristopherWevill, Yuki Ruzsicska, Donna
Woltring, Rebecca Cass, Cain Hendy, Shennelle Waters, Shae Tozer,
Erin Gargan, Nicole Smitran, Amy Llewellyn, Katrina Lawrence, Jes-
sie Spargo, Kim Hare. PREVIX data manager: Jemima Beissbarth
PREVIX statistician: Mark Chatfield (to Dec 2017), Victor
Oguoma (from Jan 2018), Zhiqiang Wang (2020).
Community Workers: Jeanette Warnir and Georgina Parmbuk
(Wadeye), Amanda Turner (Alice Springs), Kaylene Puruntatameri
(Wurrumiyanga)
Clinic managers and midwives: Tracy Porter & Sharon Overend,
Kris O’Connell & Sophie Eakins, Kim Henschke &Maree Daniel, Eve-
lyn Semmens & Amy Richie
iDSMB members: David Isaacs (Chair), Hasantha Gunasekera,
Terry Nolan, Peta Forder, Heather D’Antoine, Nicholas Wood6. Trial registration
ACTRN12610000544077 and NCT01174849. Status - closed13Funding
Australian National Health and Medical Research Council
(GNT605810) and Financial Markets for Children.
Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
to influence the work reported in this paper.
Acknowledgements
The PREVIX_COMBO trial is funded by the Australian National
Health and Medical Research Council, NHMRC (GNT605810). AJL
was supported by a NHMRC Senior Research Fellowship
(GNT1020561). PVL was supported by a NHMRC Career Develop-
ment Fellowship (GNT1146198). Opsonophagocytic Activity
(OPA) assays were funded by Financial Markets for Children (Grant
number 2012-057). The trial sponsor is the Menzies School of
Health Research, PO Box 41096, Casuarina, 0811, Northern Terri-
tory, Australia. GlaxoSmithKline provided reagents necessary for
the protein D immunogenicity assays.
Protocol deviations and protocol violations can be provided on
written request.Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.jvacx.2021.100086.
References
[1] Leach AJ, Boswell JB, Asche V, Nienhuys TG, Mathews JD. Bacterial colonization
of the nasopharynx predicts very early onset and persistence of otitis media in
Australian Aboriginal infants. Pediatr Infect Dis J 1994;13(11):983–9. https://
doi.org/10.1097/00006454-199411000-00009.
[2] Leach AJ, Wigger C, Beissbarth J, et al. General health, otitis media,
nasopharyngeal carriage and middle ear microbiology in Northern Territory
Aboriginal children vaccinated during consecutive periods of 10-valent or 13-
valent pneumococcal conjugate vaccines. Int J Pediatr Otorhinolaryngol
2016;86:224–32. https://doi.org/10.1016/j.ijporl.2016.05.011.
[3] Su JY, He VY, Guthridge S, Howard D, Leach A, Silburn S. The impact of hearing
impairment on Aboriginal children’s school attendance in remote Northern
Territory: a data linkage study. Aust N Z J Public Health 2019;43(6):544–50.
https://doi.org/10.1111/1753-6405.12948.
[4] He VY, Su JY, Guthridge S, et al. Hearing and justice: The link between hearing
impairment in early childhood and youth offending in Aboriginal children
living in remote communities of the Northern Territory. Australia. Health
Justice 2019;7(1):16–28. https://doi.org/10.1186/s40352-019-0097-6.
[5] Russell DJ, Zhao Y, Guthridge S, et al. Patterns of resident health workforce
turnover and retention in remote communities of the Northern Territory of
Australia, 2013–2015. Human Resources for Health 2017;15(1):52. https://doi.
org/10.1186/s12960-017-0229-9.
[6] Prymula R, Kriz P, Kaliskova E, Pascal T, Poolman J, Schuerman L. Effect of
vaccination with pneumococcal capsular polysaccharides conjugated to
Haemophilus influenzae-derived protein D on nasopharyngeal carriage of
Streptococcus pneumoniae and H. influenzae in children under 2 years of age.
Vaccine 2009;28(1):71–8. https://doi.org/10.1016/j.vaccine.2009.09.113.
[7] Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides
conjugated to protein D for prevention of acute otitis media caused by both
Streptococcus pneumoniae and non-typable Haemophilus influenzae: a
randomised double-blind efficacy study. Lancet 2006;367(9512):740–8.
https://doi.org/10.1016/S0140-6736(06)68304-9.
[8] Scott JA, Ojal J, Ashton L, Muhoro A, Burbidge P, Goldblatt D. Pneumococcal
conjugate vaccine given shortly after birth stimulates effective antibody
concentrations and primes immunological memory for sustained infant
protection. Clin Infect Dis 2011;53(7):663–70. https://doi.org/
10.1093/cid/cir444.
[9] Barzilay EJ, O’Brien KL, Kwok YS, et al. Could a single dose of pneumococcal
conjugate vaccine in children be effective?: Modeling the optimal age of
vaccination. Vaccine 2006;24(7):904–13. https://doi.org/10.1016/
j.vaccine.2005.08.092.
[10] Silfverdal SA, Hogh B, Bergsaker MR, et al. Immunogenicity of a 2-dose priming
and booster vaccination with the 10-valent pneumococcal nontypeable
Amanda Jane Leach, Edward Kim Mulholland, M. Santosham et al. Vaccine: X 7 (2021) 100086Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J
2009;28(10):e276–82. https://doi.org/10.1097/INF.0b013e3181b48ca3.
[11] Grimprel E, Laudat F, Patterson S, et al. Immunogenicity and safety of a 13-
valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose
to children immunized with PCV7 as infants. Vaccine 2011;29(52):9675–83.
https://doi.org/10.1016/j.vaccine.2011.10.012.
[12] Leach AJ, Mulholland EK, Santosham M, et al. Pneumococcal conjugate
vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk
Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled
trial. BMJ open 2015;5(1):e007247–e7257. https://doi.org/10.1136/bmjopen-
2014-007247.
[13] Licciardi PV, Russell FM, Balloch A, et al. Impaired serotype-specific immune
function following pneumococcal vaccination in infants with prior carriage.
Vaccine 2014;32(20):2321–7. https://doi.org/10.1016/j.vaccine.2014.02.064.
[14] Statacorp. Stata Statistical Software: Release 15. College Station, Texas: Stata
Corporation; 2017.
[15] Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and
correlates of protection for the 13-valent pneumococcal conjugate vaccine: a
postlicensure indirect cohort study. Lancet Infect Dis 2014;14(9):839–46.
https://doi.org/10.1016/S1473-3099(14)70822-9.
[16] Madhi SA, Violari A, Klugman KP, et al. Inferior quantitative and qualitative
immune responses to pneumococcal conjugate vaccine in infants with
nasopharyngeal colonization by Streptococcus pneumoniae during the
primary series of immunization. Vaccine 2011;29(40):6994–7001. https://
doi.org/10.1016/j.vaccine.2011.07.035.
[17] Voysey M, Fanshawe TR, Kelly DF, et al. Serotype-Specific Correlates of
Protection for Pneumococcal Carriage: An Analysis of Immunity in 19
Countries. Clin Infect Dis 2018;66(6):913–20. https://doi.org/
10.1093/cid/cix895.
[18] Prymula R, Hanovcova I, Splino M, et al. Impact of the 10-valent pneumococcal
non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV)
on bacterial nasopharyngeal carriage. Vaccine 2011;29(10):1959–67. https://
doi.org/10.1016/j.vaccine.2010.12.086.
[19] Almudevar A, Pichichero ME. Haemophilus influenzae-protein D specific
antibody correlate with protection against acute otitis media in young
children. Vaccine 2018;36(9):1133–5. https://doi.org/10.1016/
j.vaccine.2018.01.021.14[20] Nicholls TR, Leach AJ, Morris PS. The short-term impact of each primary dose of
pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic
review and meta-analyses of randomised controlled trials. Vaccine 2016;34
(6):703–13. https://doi.org/10.1016/j.vaccine.2015.12.048.
[21] O’Grady KF, Chang AB, Cripps A, et al. The clinical, immunological and
microbiological impact of the 10-valent pneumococcal-Protein D conjugate
vaccine in children with recurrent protracted bacterial bronchitis, chronic
suppurative lung disease and bronchiectasis: A multi-centre, double-blind,
randomised controlled trial. Hum Vaccin Immunother 2018;14(11):2768–79.
https://doi.org/10.1080/21645515.2018.1488562.
[22] Hare KM, Smith-Vaughan HC, Leach AJ, Pizzutto SJ, McCallum GB, Chang AB.
Reduced nontypeable Haemophilus influenzae lower airway infection in
children with chronic endobronchial suppuration vaccinated with the 10-
valent pneumococcal H. influenzae protein D conjugate vaccine. Vaccine
2018;36(13):1736–42. https://doi.org/10.1016/j.vaccine.2018.02.054.
[23] Leach AJ, Wigger C, Hare K, et al. Reduced middle ear infection with non-
typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after
transition to 10-valent pneumococcal non-typeable H. influenzae protein D
conjugate vaccine. BMC pediatrics 2015;15(1):162–75. https://doi.org/
10.1186/s12887-015-0483-8.
[24] Leach AJ, Wigger C, Andrews R, Chatfield M, Smith-Vaughan H, Morris PS.
Otitis media in children vaccinated during consecutive 7-valent or 10-valent
pneumococcal conjugate vaccination schedules. BMC pediatrics 2014;14
(1):200–11. https://doi.org/10.1186/1471-2431-14-200.
[25] Temple B, Toan NT, Dai VTT, et al. Immunogenicity and reactogenicity of ten-
valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho
Chi Minh City, Vietnam: a randomised controlled trial. Lancet Infect Dis
2019;19(5):497–509. https://doi.org/10.1016/s1473-3099(18)30734-5.
[26] Pomat WS, van den Biggelaar AHJ, Wana S, et al. Safety and Immunogenicity of
Pneumococcal Conjugate Vaccines in a High-risk Population: A Randomized
Controlled Trial of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine
in Papua New Guinean Infants. Clin Infect Dis 2019;68(9):1472–81. https://
doi.org/10.1093/cid/ciy743.
[27] Nieto Guevara J, Borys D, DeAntonio R, Guzman-Holst A, Hoet B.
Interchangeability between pneumococcal conjugate vaccines for pediatric
use: a systematic literature review. Expert Rev Vaccines 2019:1–12. https://
doi.org/10.1080/14760584.2019.1688148.
